Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease.

"Declarations Conflict of interestE. Berger-Sieczkowski, V. Endmayr, C. Haider, G. Ricken, P. Jauk, S. Macher, Schnider, E. Bradley-Zechmeister, R. Reinecke, Reinecke Raphael, G. Kasprian, C. Weber, M. Bergmann, C. Gaig, L. Sabater, and E. Gelpi report no relevant disclosures. I. Koneczny has participated in meetings sponsored by Alexion. I. Milenkovic has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from: UCB, Sanofi-Genzyme, BioMarin and Takeda. A. Heidbreder reports speaker honoraria for UCB, Bioprojet, Idorsia, Medice, Jazz Pharmaceuticals. B. Högl reports speaker honoraria Jazz and Abbvie and advisor feed from Lundbeck. S. Mariotto reports speaker honoraria from Biogen, Sanofy, and Novartis. T. Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Biogen, Biologix, Bionorica, BMS/Celgene, Eisei, Janssen-Cilag, MedDay, Merck, Novartis, Roche, Sandoz, Sanofi-Genzyme, Teva, UCB. His institution has received financial support in the past 12 months by unrestricted research grants (Bayer, Biogen, BMS/Celgene, Merck, Novartis, Roche, Sanofi-Genzyme, Teva) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, BMS/Celgene, Merck, Novartis, Roche, Sanofi-Aventis, Teva. R. Höftberger reports speaker honoraria from Novartis and Biogen. The Medical University of Vienna (Austria; employer of Dr. Höftberger) receives payment for antibody assays and for antibody validation experiments organized by Euroimmun (Lübeck, Germany). Dr. F. Graus holds a patent licensed to Euroimmun for the use of IgLON5 in an autoantibody test, for which he receives royalties, and receives honoraria from MedLink Neurology for his role as associate editor. W. Pirker attended advisory boards by Stada, AbbVie Pharma, Merz and Bial. He received travel grants and educational support from Boehringer Ingelheim, AOP Pharma as well as lecturing honoraria from GE, UCB, Bial, Stada, AOP Orphan, AbbVie, Medtronic and Merz Pharma. Conflict of interest E. Berger-Sieczkowski, V. Endmayr, C. Haider, G. Ricken, P. Jauk, S. Macher, Schnider, E. Bradley-Zechmeister, R. Reinecke, Reinecke Raphael, G. Kasprian, C. Weber, M. Bergmann, C. Gaig, L. Sabater, and E. Gelpi report no relevant disclosures. I. Koneczny has participated in meetings sponsored by Alexion. I. Milenkovic has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from: UCB, Sanofi-Genzyme, BioMarin and Takeda. A. Heidbreder reports speaker honoraria for UCB, Bioprojet, Idorsia, Medice, Jazz Pharmaceuticals. B. Högl reports speaker honoraria Jazz and Abbvie and advisor feed from Lundbeck. S. Mariotto reports speaker honoraria from Biogen, Sanofy, and Novartis. T. Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Biogen, Biologix, Bionorica, BMS/Celgene, Eisei, Janssen-Cilag, MedDay, Merck, Novartis, Roche, Sandoz, Sanofi-Genzyme, Teva, UCB. His institution has received financial support in the past 12 months by unrestricted research grants (Bayer, Biogen, BMS/Celgene, Merck, Novartis, Roche, Sanofi-Genzyme, Teva) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, BMS/Celgene, Merck, Novartis, Roche, Sanofi-Aventis, Teva. R. Höftberger reports speaker honoraria from Novartis and Biogen. The Medical University of Vienna (Austria; employer of Dr. Höftberger) receives payment for antibody assays and for antibody validation experiments organized by Euroimmun (Lübeck, Germany). Dr. F. Graus holds a patent licensed to Euroimmun for the use of IgLON5 in an autoantibody test, for which he receives royalties, and receives honoraria from MedLink Neurology for his role as associate editor. W. Pirker attended advisory boards by Stada, AbbVie Pharma, Merz and Bial. He received travel grants and educational support from Boehringer Ingelheim, AOP Pharma as well as lecturing honoraria from GE, UCB, Bial, Stada, AOP Orphan, AbbVie, Medtronic and Merz Pharma."

"Funding Open access funding provided by Austrian Science Fund (FWF). This study has been partly funded by grants from the Austrian Science Fund FWF: SYNABS, I4685-B (R.H., V.E.), I6565-B (R.H., R.R.), DOC 33-B27 (R.H.) and T996-B30 (I.K.), the Austrian Society of Neurology (Österreichische Gesellschaft für Neurologie) (R.H., T.B.) and Instituto de Salud Carlos III through the project FIS21/00165 (L.S., C.G.) (co-funded by the European Regional Development Fund "Investing in your future"). We thank the European Joint Programme on Rare Diseases (EJPRD) for funding a Networking event (contract number 463001015) on IgLON5 disease (L.S, C.G, F.G, E.G, R.H) from the European Union’s Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP Nº825575. IDIBAPS belongs to CERCA (Centres de recerca de Calalunya)."